Bruno Medeiros on How to Interpret AML Clinical Trial Data

In the emerging era of personalized treatment, it may be time to rethink which surrogate markers are used in AML clinical trials.

Source: CancerNetwork - July 20, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news